Influenza vaccine programs for children in low- and middle-income countries: current status and way forward
Introduction: Influenza vaccines are safe and effective, yet they are infrequently used in low- and middle-income countries (LMICs). Areas covered: We examine influenza vaccine programs for children from within a framework of new vaccine adoption in LMICs. We review the available evidence on disease...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-07-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/14760584.2019.1635462 |
| _version_ | 1797680337424220160 |
|---|---|
| author | Justin R Ortiz Kathleen M Neuzil |
| author_facet | Justin R Ortiz Kathleen M Neuzil |
| author_sort | Justin R Ortiz |
| collection | DOAJ |
| description | Introduction: Influenza vaccines are safe and effective, yet they are infrequently used in low- and middle-income countries (LMICs). Areas covered: We examine influenza vaccine programs for children from within a framework of new vaccine adoption in LMICs. We review the available evidence on disease burden and vaccine introduction, the current global and financing policies, and the current status of vaccine availability, and country readiness for implementation. Expert commentary: Access to appropriate formulations of influenza vaccines and existing immunization infrastructures must be strengthened if influenza vaccine programs are to be expanded in LMICs. While WHO recommends that implementation of influenza vaccine programs should be a country decision based on national goals, capacities, and data review, vaccine decision makers from many LMICs will likely need more evidence to inform the value proposition of program investment for pediatric vaccination, particularly related to alternative immunization strategies that align with current vaccine delivery platforms, anticipated program impact on severe illness endpoints, and program costs and economic benefits. Targeted research and development to address the specific needs of LMICs may be needed to demonstrate the value proposition of influenza vaccines and to expand influenza vaccine programs in these settings. |
| first_indexed | 2024-03-11T23:28:32Z |
| format | Article |
| id | doaj.art-1210012da2c343ff9e31bdd5604cd3c3 |
| institution | Directory Open Access Journal |
| issn | 1476-0584 1744-8395 |
| language | English |
| last_indexed | 2024-03-11T23:28:32Z |
| publishDate | 2019-07-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj.art-1210012da2c343ff9e31bdd5604cd3c32023-09-20T10:18:04ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952019-07-0118771172410.1080/14760584.2019.16354621635462Influenza vaccine programs for children in low- and middle-income countries: current status and way forwardJustin R Ortiz0Kathleen M Neuzil1University of Maryland School of MedicineUniversity of Maryland School of MedicineIntroduction: Influenza vaccines are safe and effective, yet they are infrequently used in low- and middle-income countries (LMICs). Areas covered: We examine influenza vaccine programs for children from within a framework of new vaccine adoption in LMICs. We review the available evidence on disease burden and vaccine introduction, the current global and financing policies, and the current status of vaccine availability, and country readiness for implementation. Expert commentary: Access to appropriate formulations of influenza vaccines and existing immunization infrastructures must be strengthened if influenza vaccine programs are to be expanded in LMICs. While WHO recommends that implementation of influenza vaccine programs should be a country decision based on national goals, capacities, and data review, vaccine decision makers from many LMICs will likely need more evidence to inform the value proposition of program investment for pediatric vaccination, particularly related to alternative immunization strategies that align with current vaccine delivery platforms, anticipated program impact on severe illness endpoints, and program costs and economic benefits. Targeted research and development to address the specific needs of LMICs may be needed to demonstrate the value proposition of influenza vaccines and to expand influenza vaccine programs in these settings.http://dx.doi.org/10.1080/14760584.2019.1635462influenzainfluenza vaccinelow-resource countryimmunizationpediatrics |
| spellingShingle | Justin R Ortiz Kathleen M Neuzil Influenza vaccine programs for children in low- and middle-income countries: current status and way forward Expert Review of Vaccines influenza influenza vaccine low-resource country immunization pediatrics |
| title | Influenza vaccine programs for children in low- and middle-income countries: current status and way forward |
| title_full | Influenza vaccine programs for children in low- and middle-income countries: current status and way forward |
| title_fullStr | Influenza vaccine programs for children in low- and middle-income countries: current status and way forward |
| title_full_unstemmed | Influenza vaccine programs for children in low- and middle-income countries: current status and way forward |
| title_short | Influenza vaccine programs for children in low- and middle-income countries: current status and way forward |
| title_sort | influenza vaccine programs for children in low and middle income countries current status and way forward |
| topic | influenza influenza vaccine low-resource country immunization pediatrics |
| url | http://dx.doi.org/10.1080/14760584.2019.1635462 |
| work_keys_str_mv | AT justinrortiz influenzavaccineprogramsforchildreninlowandmiddleincomecountriescurrentstatusandwayforward AT kathleenmneuzil influenzavaccineprogramsforchildreninlowandmiddleincomecountriescurrentstatusandwayforward |